Mahkam Zanganeh - Dec 11, 2023 Form 4 Insider Report for Summit Therapeutics Inc. (SMMT)

Role
Chief Executive Officer, Director
Signature
/s/ Mahkam Zanganeh
Stock symbol
SMMT
Transactions as of
Dec 11, 2023
Transactions value $
$1,214,458
Form type
4
Date filed
12/13/2023, 05:11 PM
Previous filing
Nov 15, 2023
Next filing
Mar 27, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SMMT Common Stock Exercise of in-the-money or at-the-money derivative security $705K +490K $1.44 490K Dec 11, 2023 Direct F1
transaction SMMT Common Stock Purchase $10.4K +5K +1.02% $2.07 495K Dec 12, 2023 Direct F2
transaction SMMT Common Stock Exercise of in-the-money or at-the-money derivative security $499K +316K +1.28% $1.58 24.9M Dec 11, 2023 By the Mahkam Zanganeh Revocable Trust, with the Reporting Person as Trustee F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SMMT Warrant (right to buy) Exercise of in-the-money or at-the-money derivative security $0 -490K -100% $0.00* 0 Dec 11, 2023 Common Stock 490K $1.44 Direct F1
transaction SMMT Warrant (right to buy) Exercise of in-the-money or at-the-money derivative security $0 -316K -100% $0.00* 0 Dec 11, 2023 Common Stock 316K $1.58 By the Mahkam Zanganeh Revocable Trust, with the Reporting Person as Trustee F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person exercised certain warrants to purchase shares of common stock in accordance with the terms of such warrants.
F2 The Reporting Person purchased these shares in a single transaction on the open market.
F3 The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.